Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of “Buy” by Analysts

Maze Therapeutics, Inc. (NASDAQ:MAZE) has earned a consensus rating of “Buy” from the eleven research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $44.50.

A number of research firms recently commented on MAZE. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price objective for the company. Wedbush increased their target price on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. HC Wainwright upped their price target on Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. increased their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research note on Monday, September 29th.

Maze Therapeutics Trading Down 4.2%

NASDAQ MAZE opened at $44.27 on Friday. Maze Therapeutics has a 1 year low of $6.71 and a 1 year high of $47.36. The company has a market cap of $2.13 billion and a PE ratio of -2.12. The stock’s 50-day moving average price is $39.90 and its two-hundred day moving average price is $27.97.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Insider Buying and Selling

In other Maze Therapeutics news, insider Atul Dandekar sold 72,400 shares of the stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $2,936,544.00. Following the completion of the sale, the insider owned 10,503 shares in the company, valued at $426,001.68. This represents a 87.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $39.15, for a total transaction of $195,750.00. Following the sale, the senior vice president directly owned 12,965 shares of the company’s stock, valued at $507,579.75. This trade represents a 27.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 167,500 shares of company stock worth $6,774,667.

Institutional Trading of Maze Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. CWM LLC acquired a new position in shares of Maze Therapeutics during the 2nd quarter worth $28,000. Ameritas Investment Partners Inc. boosted its holdings in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Maze Therapeutics during the third quarter worth $52,000. Finally, Legal & General Group Plc raised its holdings in Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after buying an additional 3,371 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.